AU1321900A - Compositions and methods employing r(-) fluoxetine and other active ingredients - Google Patents

Compositions and methods employing r(-) fluoxetine and other active ingredients

Info

Publication number
AU1321900A
AU1321900A AU13219/00A AU1321900A AU1321900A AU 1321900 A AU1321900 A AU 1321900A AU 13219/00 A AU13219/00 A AU 13219/00A AU 1321900 A AU1321900 A AU 1321900A AU 1321900 A AU1321900 A AU 1321900A
Authority
AU
Australia
Prior art keywords
fluoxetine
compositions
active ingredients
methods employing
employing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13219/00A
Inventor
Timothy J Barberich
Dean A. Handley
Paul D. Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AU1321900A publication Critical patent/AU1321900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU13219/00A 1998-10-23 1999-10-22 Compositions and methods employing r(-) fluoxetine and other active ingredients Abandoned AU1321900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17770398A 1998-10-23 1998-10-23
US09177703 1998-10-23
PCT/US1999/024970 WO2000024399A1 (en) 1998-10-23 1999-10-22 Compositions and methods employing r(-) fluoxetine and other active ingredients

Publications (1)

Publication Number Publication Date
AU1321900A true AU1321900A (en) 2000-05-15

Family

ID=22649648

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13219/00A Abandoned AU1321900A (en) 1998-10-23 1999-10-22 Compositions and methods employing r(-) fluoxetine and other active ingredients

Country Status (2)

Country Link
AU (1) AU1321900A (en)
WO (1) WO2000024399A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123490A1 (en) * 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
CA2539426C (en) 2003-09-17 2012-07-10 Janssen Pharmaceutica, Nv Fused heterocyclic compounds
JPWO2006093192A1 (en) * 2005-03-04 2008-08-07 国立大学法人 東京医科歯科大学 Stimulant psychosis and schizophrenia relapse prevention drug
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CN106061506A (en) 2014-02-07 2016-10-26 纽罗克里生物科学有限公司 Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
FI3875459T3 (en) 2015-10-30 2024-02-14 Neurocrine Biosciences Inc Valbenazine dihydrochloride salts and polymorphs thereof
HUE059065T2 (en) 2015-12-23 2022-10-28 Neurocrine Biosciences Inc Synthetic method for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]lsoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
AU2017395703B2 (en) 2017-01-27 2021-09-23 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP7250006B2 (en) 2017-09-21 2023-03-31 ニューロクライン バイオサイエンシーズ，インコーポレイテッド High-Dose Valbenazine Formulations and Related Compositions, Methods and Kits
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP2021502959A (en) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Methods for Administering Specific VMAT2 Inhibitors
AU2019322863B2 (en) 2018-08-15 2025-02-27 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
AU4100699A (en) * 1998-05-28 1999-12-13 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients

Also Published As

Publication number Publication date
WO2000024399A1 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
AU7429100A (en) Chondrocyte compositions, preparation and use thereof
AU4099199A (en) Encapsulated breakers, compositions and methods of use
AU3572599A (en) Analgesic compositions comprising nmda-antagonists and abt-594
AU2487699A (en) Alteration of amino acid compositions in seeds
AU2091499A (en) Permeable compositions and methods for their preparation
AU3671099A (en) Methods and compositions pertaining to pd-loops
HK1041639A1 (en) Stable amorphous amifostine compositions and methods for the preparation and use of same.
AU2349399A (en) R-lansoprazole compositions and methods
AU2660900A (en) 4-haloalkyl-3-heterocyclylpyridines and 4-haloalkyl-5-heterocyclyl-pyrimidines and their use as repellents
AU5565099A (en) Pharmaceutical compositions and methods for use
AU1321900A (en) Compositions and methods employing r(-) fluoxetine and other active ingredients
AU4100699A (en) Compositions and methods employing r(-) fluoxetine and other active ingredients
AU6408898A (en) Antimicrobial compositions, their preparation and use
AU2184099A (en) Insecticidal compositions and insecticidal methods
AU4996100A (en) (s,r) formoterol methods and compositions
AU1969800A (en) Combination of active agents
AU5965399A (en) Pharmaceutically active composition
AU1152601A (en) Compositions and their use
AU4981199A (en) Compositions and methods for modulating sexual activity
AU6033696A (en) Detergent compositions comprising polyamine scavenger agents and enzymes
AU1558700A (en) Combinations of active ingredients
AU5032499A (en) Dye-transfer-inhibiting compositions and particulate detergent compositions containing them
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU3558799A (en) Flutamide compositions and preparations
AU2713300A (en) Stable aqueous enzyme compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase